Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report

Ichiro Takeuchi; Kosuke Taniguchi; Katsuhiro Arai; Toru Uchiyama; Miho Terao; Asuka Hori; Toshinao Kawai; Takako Yoshioka; Reiko Kyodo; Hirotaka Shimizu; Satoshi Fujita; Kenichiro Motomura; Yuka Okazaki; Takashi Ishikawa; Masao Ogura; Kentaro Hayashi; Kenji Matsumoto; Shuji Takada; Masafumi Onodera; Hideaki Morita; Kenichiro Hata

doi:10.5217/ir.2024.00190

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Case Report Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report: Ichiro Takeuchi^1,, Kosuke Taniguchi^2,3,*, Katsuhiro Arai¹, Toru Uchiyama⁴, Miho Terao⁵, Asuka Hori², Toshinao Kawai⁶, Takako Yoshioka⁷, Reiko Kyodo¹, Hirotaka Shimizu¹, Satoshi Fujita^8,9, Kenichiro Motomura⁸, Yuka Okazaki², Takashi Ishikawa⁶, Masao Ogura¹⁰, Kentaro Hayashi¹¹, Kenji Matsumoto⁸, Shuji Takada⁵, Masafumi Onodera⁶, Hideaki Morita^8,12,, Kenichiro Hata^2,3,; DOI: https://doi.org/10.5217/ir.2024.00190
Published online: April 4, 2025

¹Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan

²Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan

³Department of Human Molecular Genetics, Gunma University Graduate School of Medicine, Maebashi, Japan

⁴Department of Human Genetics, National Center for Child Health and Development, Tokyo, Japan

⁵Department of Systems BioMedicine, National Research Institute for Child Health and Development, Tokyo, Japan

⁶Division of Immunology, National Center for Child Health and Development, Tokyo, Japan

⁷Department of Pathology, National Center for Child Health and Development, Tokyo, Japan

⁸Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan

⁹Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan

¹⁰Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan

¹¹Department of Orthopedic Surgery, National Center for Child Health and Development, Tokyo, Japan

¹²Allergy Center, National Center for Child Health and Development, Tokyo, Japan

Correspondence to Ichiro Takeuchi, Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. E-mail: takeuchi-i@ncchd.go.jp

Co-Correspondence to Kenichiro Hata, Department of Maternal-Fetal Biology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. E-mail: hata-k@ncchd.go.jp

Co-Correspondence to Hideaki Morita, Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo 157-8535, Japan. E-mail: morita-hi@ncchd.go.jp

*These authors contributed equally to this study as first authors.

• Received: November 15, 2024 • Revised: February 18, 2025 • Accepted: March 4, 2025

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

580 Views
77 Download

Full Article

Download PDF

Abstract
INTRODUCTION
CASE REPORT
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Tumor necrosis factor receptor-associated factor 3 (TRAF3) is an anti-inflammatory molecule that negatively regulates the non-canonical nuclear factor-κB pathway. Although TRAF3 haploinsufficiency (TRAF3 HI) can influence innate and adaptive immune cells, its effect on inflammatory bowel disease (IBD) development remains unclear. Here, we report the first case of severe early-onset IBD with a novel TRAF3 variant leading to HI, successfully treated with ustekinumab. A 6-year-old girl with a recurrent parotitis, otitis media, tonsilitis, and atopic dermatitis developed IBD involving the stomach, small intestine, and colon. At diagnosis, the immunoglobulin (Ig)G and IgA levels were relatively high, and lymphocyte subsets showed increased counts of plasmablasts, class-switch recombination B cells, and circulating T-follicular helper cells. Treatment with azathioprine and infliximab failed to maintain remission marked by several relapses accompanied by erythema nodosum and arthritis; however, ustekinumab, an anti-interleukin (IL)-12/23p40 antibody, led to long-term clinical remission, normalizing the Ig level and reducing abnormal lymphocyte counts. Whole-exome sequencing revealed a novel heterozygous mutation in TRAF3 [p.(Pro487Leufs*8)], resulting in TRAF3 under-expression. Our case may highlight the contribution of TRAF3 HI to the development of IBD and provide insights into IBD pathophysiology, suggesting the involvement of the IL-12/23-T-follicular helper cell pathway affected by genetic mutations.
Keywords: TNF receptor-associated factor 3; Inflammatory bowel disease; Ustekinumab; Case reports

INTRODUCTION

Inflammatory bowel disease (IBD), mainly comprising Crohn’s disease (CD) and ulcerative colitis, is a chronic and idiopathic disorder affecting the gastrointestinal tract, leading to progressive gastrointestinal damage and disability [1]. Recent advances in genetics have revealed monogenic disorders with inborn errors of immunity and congenital epithelial barrier defects, resulting in the development of enterocolitis. These conditions are referred to as monogenic IBD and more than 75 genes have been identified as causatives for monogenic IBD. However, there are still many undiagnosed patients because of mutations in genes that have not yet been reported [2]. Identifying these novel genetic mutations is crucial for advancing our understanding of the pathogenesis of IBD and for developing targeted therapeutic strategies. Moreover, extensive analyses of these monogenic disorders may reveal critical roles of the mutated molecules in the pathogenesis of inflammatory diseases, including IBD [3].

Among tumor necrosis factor receptor-associated factor (TRAF) family members, TRAF3 performs unique functions as signaling adaptor proteins for the tumor necrosis factor (TNF) receptor or Toll-like receptors (TLRs). It is also a constitutive negative regulator of the non-canonical nuclear factor-κB pathway activated by various molecules, including CD40L and TLRs, thus influencing innate and adaptive immune cells [4]. Germline TRAF3 haploinsufficiency (TRAF3 HI) results in recurrent bacterial infections, autoimmune disorders such as Sjogren’s syndrome, B cell lymphoproliferation, and hypergammaglobulinemia [5]. While some cases with TRAF3 loss-of-function (LoF) variants reportedly involved gastrointestinal symptoms suggestive of IBD [5,6], its effect on IBD development remains unclear due to the lack of detailed information on clinical features.

This is the first report of severe early-onset IBD in a girl with a novel heterozygous pathogenic variant of TRAF3 [p.(Pro487-Leufs*8)] who was successfully treated with the anti-interleukin (IL)-12/23p40 monoclonal antibody ustekinumab.

CASE REPORT

A 6-year-old girl with a medical history of recurrent otitis media since the age of 1, parotitis since the age of 4, tonsilitis, and atopic dermatitis was admitted to our hospital because of bloody diarrhea and fever that had persisted for 1 month. The patient had no family history of autoinflammatory or autoimmune diseases. Gastrointestinal endoscopy revealed multiple small ulcerations on the edematous mucosa in her stomach, small intestine, and colon as well as pathological findings of cryptitis, and crypt abscess (Fig. 1A-C), leading to a diagnosis of CD. The patient’s condition was complicated by aseptic osteomyelitis at the right distal tibia and calcaneus, lip erosion, and blisters on the back (Fig. 1D-F). Total and differential leukocyte quantification, immunoglobulin (Ig) assay, lymphocyte analysis, and dihydrorhodamine test showed no findings suggesting primary immunodeficiency. However, immune profiling indicated increased levels of IgG and IgA and decreased counts of CD3⁺ and CD4⁺ cells at diagnosis compared with their reference ranges (Table 1). Moreover, the counts of plasmablasts, class-switch recombination B cells, and circulating T-follicular helper (cTfh) cells were relatively high (Table 1).

Initial treatment with corticosteroids was effective, but subsequent therapies with azathioprine and infliximab, an anti-TNF drug, failed to maintain remission, marked by several relapses accompanied by erythema nodosum and arthritis. Upon IBD relapse, parotitis also recurred. Magnetic resonance imaging findings revealed an apple tree pattern in the right parotid gland, consistent with Sjogren’s syndrome presentation (Fig. 1G). For anti-TNF failure in CD, ustekinumab was introduced at 7 years of age. Although temporary escalation of corticosteroids for recurrence of arthritis was required at 8 years of age, ustekinumab treatment was effective, allowing for the tapering of corticosteroids to 0.02 mg/kg and maintaining the remission of gastrointestinal manifestations and other comorbidities, including aseptic osteomyelitis and arthritis, over 4 years (Fig. 1A lower panel, Table 2). Moreover, the IgG and IgA levels improved to the normal range and the counts of plasmablasts, class-switch recombination B cells, and cTfh cells decreased after ustekinumab treatment (Table 1).

Given that the patient’s early-onset intractable IBD was complicated by aseptic osteomyelitis, lip erosion, and blisters, familial-based whole-exome sequencing was performed to identify the genetic etiology of the disease [9]. For causal variants of the narrowed results, the American College of Medical Genetics/Association for Molecular Pathology (ACMG/AMP) criteria were used [10]. A de novo heterozygous variant was identified on TRAF3 (NM_145725.3, c.1457del [p.(Pro487Leufs*8)], ClinVar accession number: SCV003843246) (Fig. 1H and I).

As this variant is absent in the Genome Aggregation Database, we considered it to be pathogenic based on ACMG/AMP criteria.

To clarify the effect of this variant on TRAF3 protein expression, we analyzed TRAF3 expression in the patient’s peripheral blood mononuclear cells (PBMCs) and T cells using Western blotting. TRAF3 protein expression in PBMCs and T cells was markedly reduced compared with that in controls (Fig. 1J), suggesting TRAF3 HI is related to its variant.

This study was approved by the Institutional Review Board of the National Center for Child Health and Development, Tokyo, Japan (#378, #926). Written informed consent was obtained from the patient’s parents, and assent was obtained from the patient. The detailed methods are presented in the Supplementary Materials.

DISCUSSION

In total, 12 patients with TRAF3 LoF variants in 7 families have been reported (Supplementary Table 1) [5,6]. The manifestations in them were considerably similar to those in our patient, including recurrent parotitis, otitis media, tonsilitis, atopic dermatitis, arthritis, increased levels of Igs, decreased counts of CD3⁺ and CD4⁺ cells, and increased count of cTfh cells [5]. Among the 4 patients with gastrointestinal involvement, 1 patient with common variable immunodeficiency, harboring p.Gln407* in TRAF3, developed pancolitis and ileitis that was steroid-dependent and treated with biologics. However, detailed clinical information, including endoscopic and histopathological images, the type of biologic agent used, and treatment responsiveness, was not provided [5,6]. Therefore, the involvement of TRAF3 LoF in the development of IBD remains unclear. Myeloid cell-conditional Traf3-knockout mice exhibit increased inflammatory cytokine levels following TLR stimulation in macrophages and increased T-cell-dependent antibody responses [11]. These mice also develop exacerbated colitis induced by dextran sulfate sodium [12]. Moreover, the TRAF3 level in the plasma and colonic mucosa is higher than that in healthy individuals [13]. Together with the critical roles of TRAF3 in immune regulation, these findings suggest the involvement of TRAF3 in the pathogenesis of IBD. Among the patients with TRAF3 LoF exhibiting gastrointestinal symptoms, a truncated protein was detected in patients harboring p.Gln407*. This finding indicates the potential involvement of a dominant-negative effect in disease pathogenesis; however, a detailed functional analysis has not been performed. In contrast, truncated protein was not detected in our case (data not shown). Further studies are needed to clarify the phenotype-genotype correlation. Given that less than half of the patients with monogenic IBD with a major causative variant develop IBD [14], environmental factors, such as dysbiosis of the gut microbiota, could be crucial for the development of CD, even in monogenic disorders.

Another important finding of this study was the difference in responsiveness to anti-cytokine therapy between anti-TNF and ustekinumab, as well as the dynamics of cTfh cells before and after treatment in our patient with TRAF3 HI. CD is considered a heterogeneous disease, and the effectiveness of specific treatments varies significantly among patients. Although approximately 10%–30% of patients show no response to anti-TNF and 40%–50% lose their response over time, anti-IL-12/23p40 therapy can be beneficial to some patients who do not respond to anti-TNF [15]. Therefore, clarifying each patient’s detailed disease pathophysiology is important for the selection of a suitable treatment. Although exact mechanisms of action of anti-TNF in CD remain unclear, 1 mechanism involves neutralization of soluble and membrane-bound TNF, causing inhibition of TNF-induced signaling through its 2 receptors, TNFR1 and TNFR2 [16]. The failure of anti-TNF therapy in our patient may partially be attributed to the fact that TRAF3 is not directly involved in TNFR1 and TNFR2 signaling. In contrast, TRAF3 is vital for TLR signaling; its deficiency reportedly increases IL-12 and IL-23 production in murine macrophages [12], both of which are crucial in Tfh cell differentiation [17]. Tfh cells help B cells, supporting the formation of germinal centers that allow affinity maturation of antibody responses; they have been suggested to be involved in the pathophysiology of a wide range of inflammatory diseases, including CD [18]. Our patient with TRAF3 HI exhibited increased cTfh cell counts before ustekinumab treatment. Moreover, she was responsive to ustekinumab and the cTfh cell count reduced after treatment. These findings raise the hypothesis that the IL-12/23-Tfh pathway could play a role in the pathophysiology of CD in our patient with TRAF3 HI. Similar findings have been reported in some patients with non-monogenic CD. Peripheral blood cTfh cell frequencies are higher in patients with active CD than in those in remission, and their frequencies significantly decrease in ustekinumab responders after treatment. However, the cTfh cell counts in ustekinumab non-responders and anti-TNF responders/non-responders remain unchanged [19]. This pattern may suggest a potential involvement of the IL-12/23-Tfh pathway, as well as TRAF3, in the pathophysiology of some patients with CD.

Growing evidence suggests that CD is a heterogeneous disease, which needs stratification considering the different management strategies with various biologics, such as anti-TNF, anti-integrins, and anti-IL-12/23 or IL-23 antibodies, in addition to corticosteroids, immunomodulators, and Janus kinase inhibitors [20]. Although further studies will be required to elucidate the role of TRAF3 in the pathogenesis of IBD and more case studies are required to provide evidence for relevant targeted therapies, understanding the specific molecules/pathways affected by genetic mutations, such as TRAF3 mutations, might lead to critical insights into disease mechanisms and further understanding of IBD pathophysiology.

NOTES

Funding Source

This study was supported in part by grants from the National Center for Child Health and Development (grant numbers 2019A-3 to KA, and 2020B-10 and 2024B-24 to IT) and the Japan Agency for Medical Research and Development (AMED: grant numbers JP21ek0109489 to Hayashi K and JP24ek0410 106 to Morita H). The funders had no role in the study design, data collection and interpretation, or decision to submit the work for publication.

Conflict of Interest

Arai K received honoraria from Mitsubishi Tanabe Pharma Co., Ltd., Janssen Pharmaceutical K.K., Nippon Kayaku Co., Ltd., and AbbVie GK and research grants from Janssen Pharmaceutical K.K. and AbbVie GK. The remaining authors disclose no conflict of interest.

Data Availability Statement

Data are available upon reasonable request.

Author Contributions

Conceptualization: Takeuchi I, Taniguchi K, Arai K, Uchiyama T, Morita H. Formal analysis: Takeuchi I, Taniguchi K, Hori A. Funding acquisition: Takeuchi I, Arai K, Morita H, Hata K. Investigation: Takeuchi I, Taniguchi K, Arai K, Uchiyama T, Terao M, Kawai T, Yoshioka T, Fujita S, Motomura K, Okazaki Y, Ishikawa T, Matsumoto K, Takada S, Onodera M, Morita H, Hata K. Resources: Takeuchi I, Arai K, Kyodo R, Shimizu H, Ogura M, Hayashi K. Supervision: Arai K, Matsumoto K, Onodera M, Morita H, Hata K. Writing - original draft: Takeuchi I, Taniguchi K, Uchiyama T, Morita H. Writing - review & editing: Arai K, Terao M, Hori A, Kawai T, Yoshioka T, Kyodo R, Shimizu H, Fujita S, Motomura K, Okazaki Y, Ishikawa T, Ogura M, Hayashi K, Matsumoto K, Takada S, Onodera M, Hata K. Approval of final manuscript: all authors.

Additional Contributions

We thank the patient and her family for their sincere efforts and cooperation during this study. We also want to express our sincere gratitude to all members of the National Center for Child Health and Development.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Materials.

ir-2024-00190-Supplementary-Materials.pdf

Supplementary Table 1.

Summary of the Patient in Our Study and Individuals with TRAF3 LoF Variants Reported in Previous Studies

ir-2024-00190-Supplementary-Table-1.pdf

Fig. 1.

Clinical characteristics and a novel heterozygous TRAF3 mutation in a patient with early-onset inflammatory bowel disease (IBD). (A) Endoscopic findings of the patient with IBD. Multiple small ulcers on the edematous mucosa in the stomach, small intestine, and colon at diagnosis (upper panels) improved after ustekinumab treatment (lower panels). (B) Findings of small bowel capsule endoscopy. Multiple erosions and small ulcers from the jejunum to the ileum (arrows). (C) Histopathological findings with cryptitis in the colon at diagnosis (hematoxylin and eosin staining, ×200). (D) Oral ulcers and (E) blisters on the back at diagnosis. (F) Positron emission tomography/computed tomography findings of the right osteomyelitis. ¹⁸F-FDG PET uptake was observed at the distal tibia and calcaneus. (G) Magnetic resonance imaging finding of parotitis with IBD recurrence. An apple tree pattern compatible with Sjogren’s syndrome manifestation was observed in the right parotid gland. (H) Family pedigree of the patient. Circles indicate female individuals, squares indicate male individuals, and the filled circle indicates our patient. The other family members did not carry the TRAF3 variant. (I) Schematic representation of the TRAF3 protein. (J) Western blot analysis of TRAF3 expression in peripheral blood mononuclear cells and T cells from the patient and control groups (n=2). ¹⁸F-FDG PET, ¹⁸F-fluorodeoxyglucose positron emission tomography; TRAF3, tumor necrosis factor receptor-associated factor 3; PBMC, peripheral blood mononuclear cell; ACTB, β actin.

Table 1.

Immunologic Characteristics of the Patient with TRAF3 Haploinsufficiency

Age at evaluation	Before UST	Under UST	Reference range [7,8]
Age at evaluation	6 yr (at diagnosis)	11 yr (remission with UST)	Reference range [7,8]
Absolute lymphocyte count (cells/μL)	1,200	1,100	1,900–3,700
Lymphocyte subsets
CD3⁺ T cells (/μL)	710	889	1,200–2,600
CD4⁺ T cells (/μL)	390	523	650–1,500
CD25⁺CD127⁺ regulatory T cells (/μL)	7	18
CD45RA^-CXCR5^- (% of CD4⁺ T cells)	33	28
CD45RA^-CXCR5⁺ (% of CD4⁺ T cells)	17	9
CD8⁺ T cells (/μL)	238	285	370–1,100
CD19⁺ B cells (/μL)	215	100	270–860
CD38^highIgM- plasmablasts (/μL)	20	1
CD38⁺IgM^high transitional B cells (/μL)	3	7
CD27⁺IgM⁺ marginal zone-like B cells (% of CD19⁺ B cells)	9	30
CD27⁺IgM^- class-switched memory B cells (% of CD19⁺ B cells)	22	5
CD16⁺CD56⁺ NK cells (/μL)	61	77	100–480
CD56⁺CD3⁺ NKT cells (/μL)	13	36
Immunoglobulin profile
IgG level (mg/dL)	1,892	1,525	650–1,530^a, 780–1,730^b
IgA level (mg/dL)	272	187	38–238^a, 60–354^b
IgM level (mg/dL)	112	117	92–353^a, 100–381^b

^a,b Data from reference intervals of clinical tests in Japanese children (Tanaka et al. [8]); ^aFor 6 years of age and ^bfor 11 years of age.

TRAF3, tumor necrosis factor receptor-associated factor 3; UST, ustekinumab; CD, cluster of differentiation; CXCR, CXC chemokine receptor; NK, natural killer; Ig, immunoglobulin.

Table 2.

Clinical Features of the Patient in Our Study Compared with Those of Individuals with TRAF3 Haploinsufficiency Reported in a Previous Study

Variable	Before IFX	Under IFX	Under UST
Variable	Before IFX	7 yr (PSL 1.0–0.06 mg/kg)	7–8 yr (PSL 1.0–0.1 mg/kg)^a	8–12 yr (PSL 0.8–0.02 mg/kg)
Clinical features specific to our patient
Severe early-onset IBD	+	+	± Improving	– Well controlled
Osteomyelitis	+	–	–	–
Clinical features of TRAF3 HI in a previous study [6,9]
Recurrent parotitis	+	+	+	± Never observed after 10 yr
Arthritis	+	+	+	–
Atopic dermatitis	+	+	– Well controlled	– Well controlled
Asthma	+	– Well controlled	– Well controlled	– Well controlled
Lymphadenitis	+ Adenotonsillectomy	–	–	–
Recurrent otitis media	+ Tympanostomy tubes	–	–	–
Bronchiectasis	–	–	–	–
Recurrent sinopulmonary infections	–	–	–	–
Splenomegaly	–	–	–	–
Thyroiditis	–	–	–	–
Vasculitis	–	–	–	–
Food or drug allergy	–	–	–	–
Common variable immunodeficiency	–	–	–	–

^a Temporary escalation to 0.8 mg/kg for the recurrence of arthritis at 8 years.

TRAF3, tumor necrosis factor receptor-associated factor 3; IFX, infliximab; UST, ustekinumab; PSL, prednisolone; IBD, inflammatory bowel disease; HI, haploinsufficiency.

REFERENCES

1. Noble AJ, Nowak JK, Adams AT, Uhlig HH, Satsangi J. Defining interactions between the genome, epigenome, and the environment in inflammatory bowel disease: progress and prospects. Gastroenterology 2023;165:44–60.Article PubMed
2. Uhlig HH, Charbit-Henrion F, Kotlarz D, et al. Clinical genomics for the diagnosis of monogenic forms of inflammatory bowel disease: a position paper from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2021;72:456–473.Article PubMed PMC
3. Saito H, Tamari M, Motomura K, et al. Omics in allergy and asthma. J Allergy Clin Immunol 2024;154:1378–1390.Article PubMed
4. Häcker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol 2011;11:457–468.Article PubMed PDF
5. Rae W, Sowerby JM, Verhoeven D, et al. Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations. Sci Immunol 2022;7:eabn3800.Article PubMed
6. Urban B, Batlle-Masó L, Perurena-Prieto J, et al. Heterozygous predicted loss-of-function variants of TRAF3 in patients with common variable immunodeficiency. J Clin Immunol 2024;45:47.Article PubMed PDF
7. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003;112:973–980.PubMed
8. Tanaka T, Yamashita A, Ichihara K. Reference intervals of clinical tests in children determined by a latent reference value extraction method. J Jpn Pediatr Soc 2008;112:1117–1132.
9. Taniguchi K, Hasegawa F, Okazaki Y, et al. Re-evaluation of whole exome sequencing, including intronic region, in combination with genetic intolerance score for detecting foetal structural anomalies in X-linked disorders. medRxiv [Preprint] c2023;[cited 2025 Feb 18]. https://doi.org/10.1101/2023.02.05.23285039.Article
10. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–424.Article PubMed PMC PDF
11. Lalani AI, Moore CR, Luo C, et al. Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice. J Immunol 2015;194:334–348.Article PubMed PDF
12. Jin J, Xiao Y, Hu H, et al. Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages. Nat Commun 2015;6:5930.Article PubMed PDF
13. Shen J, Qiao YQ, Ran ZH, Wang TR. Up-regulation and preactivation of TRAF3 and TRAF5 in inflammatory bowel disease. Int J Med Sci 2013;10:156–163.Article PubMed PMC
14. Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 2014;147:990–1007.Article PubMed
15. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375:1946–1960.Article PubMed
16. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis 2016;10:989–997.Article PubMed
17. Schmitt N, Liu Y, Bentebibel SE, et al. The cytokine TGF-β coopts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells. Nat Immunol 2014;15:856–865.Article PubMed PMC PDF
18. Walker LS. The link between circulating follicular helper T cells and autoimmunity. Nat Rev Immunol 2022;22:567–575.Article PubMed PMC PDF
19. Globig AM, Sommer NP, Wild K, et al. Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease. Cell Mol Gastroenterol Hepatol 2021;11:1–12.Article PubMed
20. D’Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn’s disease: new data for positioning in treatment algorithm. J Crohns Colitis 2022;16(Suppl 2): ii30–ii41.Article PubMed PMC PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report

DOI: https://doi.org/10.5217/ir.2024.00190

XML Download

Figure

Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report

Fig. 1. Clinical characteristics and a novel heterozygous TRAF3 mutation in a patient with early-onset inflammatory bowel disease (IBD). (A) Endoscopic findings of the patient with IBD. Multiple small ulcers on the edematous mucosa in the stomach, small intestine, and colon at diagnosis (upper panels) improved after ustekinumab treatment (lower panels). (B) Findings of small bowel capsule endoscopy. Multiple erosions and small ulcers from the jejunum to the ileum (arrows). (C) Histopathological findings with cryptitis in the colon at diagnosis (hematoxylin and eosin staining, ×200). (D) Oral ulcers and (E) blisters on the back at diagnosis. (F) Positron emission tomography/computed tomography findings of the right osteomyelitis. 18F-FDG PET uptake was observed at the distal tibia and calcaneus. (G) Magnetic resonance imaging finding of parotitis with IBD recurrence. An apple tree pattern compatible with Sjogren’s syndrome manifestation was observed in the right parotid gland. (H) Family pedigree of the patient. Circles indicate female individuals, squares indicate male individuals, and the filled circle indicates our patient. The other family members did not carry the TRAF3 variant. (I) Schematic representation of the TRAF3 protein. (J) Western blot analysis of TRAF3 expression in peripheral blood mononuclear cells and T cells from the patient and control groups (n=2). 18F-FDG PET, 18F-fluorodeoxyglucose positron emission tomography; TRAF3, tumor necrosis factor receptor-associated factor 3; PBMC, peripheral blood mononuclear cell; ACTB, β actin.

Fig. 1.

Inflammatory bowel disease in a young female patient with a novel de novo TRAF3 frameshift variant responsive to ustekinumab: a case report

Age at evaluation	Before UST	Under UST	Reference range [7,8]
Age at evaluation	6 yr (at diagnosis)	11 yr (remission with UST)	Reference range [7,8]
Absolute lymphocyte count (cells/μL)	1,200	1,100	1,900–3,700
Lymphocyte subsets
CD3⁺ T cells (/μL)	710	889	1,200–2,600
CD4⁺ T cells (/μL)	390	523	650–1,500
CD25⁺CD127⁺ regulatory T cells (/μL)	7	18
CD45RA^-CXCR5^- (% of CD4⁺ T cells)	33	28
CD45RA^-CXCR5⁺ (% of CD4⁺ T cells)	17	9
CD8⁺ T cells (/μL)	238	285	370–1,100
CD19⁺ B cells (/μL)	215	100	270–860
CD38^highIgM- plasmablasts (/μL)	20	1
CD38⁺IgM^high transitional B cells (/μL)	3	7
CD27⁺IgM⁺ marginal zone-like B cells (% of CD19⁺ B cells)	9	30
CD27⁺IgM^- class-switched memory B cells (% of CD19⁺ B cells)	22	5
CD16⁺CD56⁺ NK cells (/μL)	61	77	100–480
CD56⁺CD3⁺ NKT cells (/μL)	13	36
Immunoglobulin profile
IgG level (mg/dL)	1,892	1,525	650–1,530^a, 780–1,730^b
IgA level (mg/dL)	272	187	38–238^a, 60–354^b
IgM level (mg/dL)	112	117	92–353^a, 100–381^b

Variable	Before IFX	Under IFX	Under UST
Variable	Before IFX	7 yr (PSL 1.0–0.06 mg/kg)	7–8 yr (PSL 1.0–0.1 mg/kg)^a	8–12 yr (PSL 0.8–0.02 mg/kg)
Clinical features specific to our patient
Severe early-onset IBD	+	+	± Improving	– Well controlled
Osteomyelitis	+	–	–	–
Clinical features of TRAF3 HI in a previous study [6,9]
Recurrent parotitis	+	+	+	± Never observed after 10 yr
Arthritis	+	+	+	–
Atopic dermatitis	+	+	– Well controlled	– Well controlled
Asthma	+	– Well controlled	– Well controlled	– Well controlled
Lymphadenitis	+ Adenotonsillectomy	–	–	–
Recurrent otitis media	+ Tympanostomy tubes	–	–	–
Bronchiectasis	–	–	–	–
Recurrent sinopulmonary infections	–	–	–	–
Splenomegaly	–	–	–	–
Thyroiditis	–	–	–	–
Vasculitis	–	–	–	–
Food or drug allergy	–	–	–	–
Common variable immunodeficiency	–	–	–	–

Table 1. Immunologic Characteristics of the Patient with TRAF3 Haploinsufficiency

a,b

Data from reference intervals of clinical tests in Japanese children (Tanaka et al. [8]); ^aFor 6 years of age and ^bfor 11 years of age.

TRAF3, tumor necrosis factor receptor-associated factor 3; UST, ustekinumab; CD, cluster of differentiation; CXCR, CXC chemokine receptor; NK, natural killer; Ig, immunoglobulin.

Table 2. Clinical Features of the Patient in Our Study Compared with Those of Individuals with TRAF3 Haploinsufficiency Reported in a Previous Study

Temporary escalation to 0.8 mg/kg for the recurrence of arthritis at 8 years.

TRAF3, tumor necrosis factor receptor-associated factor 3; IFX, infliximab; UST, ustekinumab; PSL, prednisolone; IBD, inflammatory bowel disease; HI, haploinsufficiency.